ArticleThoracic cancer2026
Insights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPleural mesothelioma (PM) is an aggressive cancer with limited therapeutic options and poor prognosis, necessitating comprehensive model systems for mechanistic studies and drug discovery.
methodsTumor cells were isolated from malignant pleural effusion of PM patients and subjected to primary culture and continuous passaging. Cell lines were successfully established after more than 40 continuous passages in vitro. Cell identification included morphological analysis, species identification, short tandem repeat (STR) profiling, mycoplasma detection, in vitro proliferation assays, in vivo tumorigenicity testing in NOD/SCID mice, and immunohistochemical characterization. Genomic landscapes and transcriptomic profiling were defined by whole-exome, whole-genome sequencing, and RNA-sequencing.
resultsThree Chinese-derived pleural mesothelioma cell lines (PUMC-MESO1, PUMC-MESO3, and PUMC-MESO4) were successfully established. All three cell lines exhibited epithelioid morphology with adherent growth patterns. Upon subcutaneous transplantation into NOD/SCID mice, PUMC-MESO1 and PUMC-MESO4 demonstrated tumorigenicity, while PUMC-MESO3 remained non-tumorigenic after 3 months of observation. Histopathological examination confirmed their mesothelioma origin through positive staining for mesothelial markers including calretinin, WT-1, and D2-40. Genomic analysis revealed characteristic PM genomic alterations including mutations in BAP1, NF2, and TP53, along with CDKN2A deletions. Transcriptomic analyses revealed heterogeneous molecular features among the three cell lines. Although the PUMC-MESO cell lines displayed distinct clustering patterns relative to the CCLE mesothelioma cohort, each retained transcriptomic similarities to specific established mesothelioma models. Drug sensitivity assays further demonstrated heterogeneous responses to standard therapeutic agents.
conclusionThis study reports the establishment and characterization of three novel PM cell lines. These models recapitulate key aspects of PM biology, exhibit diverse therapeutic responses, and provide a valuable new resource for investigating disease mechanisms and advancing precision oncology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.